Ask AI
CDH6 Ovarian Cancer

CME

Next-Generation CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: The Science, Strategy, and Signals to Inform Clinical Readiness

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: January 26, 2026

Expiration: July 25, 2026

Activity

Progress
1 2
Course Completed

Introduction

In this module, Isabelle Ray-Coquard, MD, PhD and Debra L. Richardson, MD discuss the emerging data for CDH6-targeting antibody–drug conjugates (ADCs) in ovarian cancer as well as the motivation and strategies for promoting equitable access to novel therapies and clinical trials.

Please note that the slide thumbnails in this activity link to a PowerPoint slideset that may be downloaded by clicking on any of the thumbnails within the activity.

Decera Clinical Education plans to measure the education impact of this activity. Some questions will be asked twice: once at the beginning of the activity and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this education activity, please take a moment to answer the following questions.

How many people with ovarian cancer do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting:

Antitumor activity of CDH6-targeted ADCs has been observed in ovarian cancers with what level of CDH6 expression?

The phase II/III REJOICE-Ovarian01 study reported which of the following outcomes for patients with high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or fallopian tube cancer treated with R-DXd?

In your clinical practice, how confident are you in identifying patients eligible for enrollment in clinical trials for ovarian cancer?